Entera Bio (NASDAQ:ENTX) Shares Down 3% – Here’s Why

Entera Bio Ltd. (NASDAQ:ENTX)’s share price dropped 3% on Wednesday . The company traded as low as $1.24 and last traded at $1.30. Approximately 285,757 shares traded hands during mid-day trading, an increase of 69% from the average daily volume of 169,135 shares. The stock had previously closed at $1.34.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ENTX. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, December 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Entera Bio Price Performance

The company has a market cap of $57.33 million, a price-to-earnings ratio of -5.00 and a beta of 1.83. The company’s 50-day simple moving average is $1.52 and its 200-day simple moving average is $1.97.

Institutional Trading of Entera Bio

Large investors have recently modified their holdings of the business. Schonfeld Strategic Advisors LLC lifted its stake in shares of Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares in the last quarter. Jane Street Group LLC increased its holdings in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after purchasing an additional 19,601 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.